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Editorial
Paul Ehrlich prophesied "magic bullet" in early 1900 [1],
but it was not until 1975 that Kohler and Milstein devel-
oped the hybridoma technology [2]. Since then hematol-
ogy and oncology have become closely intertwined and
rapidly evolving fields. New findings from laboratory-
based research are rapidly being turned into clinical appli-
cations. Within less than a decade, targeted therapy has
become a treatment of choice for many diseases, with
imatinib and rituximab representing the many recent
major breakthroughs in cancer therapy [3,4].
The growth of the internet has shrunk the world to a
mouse click, yet the dissemination of new scientific find-
ings is still very restricted. As a scientist and a clinician, I
have to squeeze out time to publish new scientific find-
ings and clinical observations. It almost always takes
months to get a manuscript published. Frequently, the
published articles are accessible only to those with sub-
scriptions. Journal of Hematology & Oncology aims to serve
as an international platform for sharing laboratory and
clinical findings in an open access format among labora-
tory scientists, physician scientists, hematologists and
oncologists. A rapid turnaround time from submission to
publication means that knowledge and new successes can
be shared in real time.
Rapid advances in molecular biology and the completion
of genome mapping from "worm to man" have led to an
explosive increase in discoveries of new genes and targets,
which result in development of new drugs and new tech-
nologies for diagnosis and therapy of medical disorders,
especially for blood and cancer diseases. Studies of tyro-
sine kinase oncogenes and signal transductions paved the
way to the discoveries of tyrosine kinase inhibitors [5].
The "magic bullet" theory has finally become a reality in
cancer therapy with the advent of novel drugs, such as
gemtuzumab ozogamycin (mylotarg), denileukin diftitox
(ontak), tositumomab (bexxar), and ibritumomab (zeva-
lin), to name a few. Studies of angiogenesis and mono-
clonal antibodies make it possible for a new modality of
cancer therapy [6]. Not until recently, ubiquitin and heat-
shock proteins were only familiar to scientists who are
"mouse doctors", but not to "human doctors". However,
proteasome inhibitors that target the ubiquinization-
pathway have virtually revolutionized therapies for multi-
ple myeloma in only a few years [7]. Epigenetic studies
have led to the development of new drugs which have
changed the lives of patients with myelodysplastic syn-
drome [8]. Clinical trials are increasingly performed in
many centers across the world.
With all these rapid developments and findings, volume
of information has grown enormously. However, many
publications are in inaccessible places, and many more
are not published until months later or not at all. A few
top-rated journals in the field of hematology and oncol-
ogy already exist. Many doctors and scientists from devel-
oping countries can not afford to pay for the access to
these expensive journals. Meanwhile, journals become
more focused and increasingly specialized.
Journal of Hematology & Oncology aims not to specialize,
rather to broaden and provide a platform for information
exchange for all studies related to blood and cancer. It
aims to include, not to exclude, all studies from basic
research, translational research, case reports, and clinical
trials. This journal allows the authors to keep the copy-
right so they can freely use and disseminate their articles
as they please. All articles published in this journal are
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repositories. Therefore, this journal aims not to restrict,
rather to make all published articles free and open to all.
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